Comments
Strides Arcolab Ltd said its tablets and capsules facility in its oncology medicine complex had received European regulatory approval.
It expected to take two products to Europe during the July-September third quarter this year.
The oral dosages facility is part of Onco Therapies Ltd, the cancer drugs arm under Strides subsidiary, Agila Specialities.
The facility, it said, was among a few European approved oral dosage oncology plants worldwide.
OTL's injectables facility is already approved by major regulatory agencies, enabling Strides to sell its products in many overseas markets.
Mr Venkat Iyer, CEO, Agila Specialties, said, “This further consolidates our global strategy of emerging as a leading provider of oncology drugs.”
In Europe, it has made 18 filings for oncology products that have potential local sales of $3.2 billion.
US approval
Strides said its antibacterial drug Polymyxin B injection had received US FDA approval.
The drug would be launched in the third quarter this year through its joint venture with US partner Sagent.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.